Updated interim data from our Phase 1 trial of FOLOTYN in cutaneous T-cell lymphoma.

‘Furthermore, at EHA, updated interim data from our Phase 1 trial of FOLOTYN in cutaneous T-cell lymphoma, a disease that is related to PTCL but follows a far more indolent clinical course, show that FOLOTYN is energetic in this population. Furthermore we’ve an ASCO abstract describing an ongoing Stage 2 trial in B-cell lymphoma, part of our commitment to further exploring FOLOTYN’s utility in a wide range of cancers.’ FOLOTYN, a folate analogue metabolic inhibitor, is the first and only medication accepted in the U.S. For the treating sufferers with relapsed or refractory peripheral T-cell lymphoma . Allos is developing FOLOTYN in other potential indications also. Information regarding the ASCO presentations and abstracts is below.Elsewhere, patients can receive transplants preemptively, or before dialysis is normally even required. Related StoriesMouse study displays active component in marijuana may delay rejection of incompatible organsNurses who use organ transplant patients encounter high levels of psychological exhaustionStudy suggests mix of MMF and CNIs can drive back rare lymphoma Morgan Grams, MD and her co-workers examined information from all adult first-period deceased donor kidney transplant recipients in america between 1995 and 2011, classifying them as preemptive, early , or past due recipients.